Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EPO906 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patupilone | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma. | one week |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability will be assessed by AEs, SAEs and out of range lab values. | every 6 weeks | |
| Radiological scans will also be completed at approximately 6 weeks to asses anti-tumor activity. | every 6 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cancer Therapy and Research Center, Institution for Drug Development | San Antonio | Texas | 78229 | United States |
Not provided
| Label | URL |
|---|---|
| Results can be found for CEPO906A2122 on the Novartis Clinical Trial Results Website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C093788 | epothilone B |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided